Medication Monitor

Generic Name (Trade Name—Company)
February 1, 2011


Maintenance therapy in advanced follicular lymphoma


Maintenance treatment of advanced follicular lymphoma in patients who responded to initial treatment with this agent plus chemotherapy (induction treatment)

Approval was based on data from the PRIMA (Primary Rituxan and Maintenance) study (n = 1,217), which showed that continuing rituximab therapy every 2 months for 2 years in patients who responded to initial treatment with rituximab plus chemotherapy nearly doubled progression-free survival compared with patients who stopped therapy (hazard ratio 0.54 [95% CI 0.42–0.70], P = 0.0001). Rituximab is also indicated for treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia and, in combination with methotrexate, to reduce structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.